{
    "clinical_study": {
        "@rank": "43711", 
        "acronym": "Kinesia-D", 
        "arm_group": {
            "arm_group_label": "Parkinson's disease on levodopa", 
            "description": "Individuals with Parkinson's disease who are taking levodopa to treat motor symptoms"
        }, 
        "brief_summary": {
            "textblock": "The objective is to assess a compact, portable, wireless movement disorder system with\n      continuous monitoring capabilities to detect and quantify the severity of levodopa-induced\n      dyskinesia in Parkinson's disease."
        }, 
        "brief_title": "Ambulatory Parkinson's Disease Dyskinesia Monitor for Drug Therapy Titration", 
        "condition": "Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of idiopathic Parkinson's disease\n\n          -  Clinical history of levodopa-induced dyskinesia\n\n          -  21 Years of age or older\n\n          -  Stage 2 - 4 OFF-medication on the Hoehn and Yahr scale\n\n        Exclusion Criteria:\n\n          -  Dementia (determined by a neuropsychological assessment)\n\n          -  Severe tremor unaffected by levodopa"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Individuals with Parkinson's disease and a history of levodopa-induced dyskinesia"
            }
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02125825", 
            "org_study_id": "KinesiaDPhaseIIYear1", 
            "secondary_id": "9R44AG044293"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 20, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins Medical Center"
                }, 
                "investigator": {
                    "last_name": "Zoltan Mari, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "University of Rochester Medical Center"
                }, 
                "investigator": {
                    "last_name": "Michelle Burack, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Kinesia-D Phase II In-Clinic Continuous Assessment Study", 
        "overall_contact": {
            "email": "cpulliam@glneurotech.com", 
            "last_name": "Christopher Pulliam, PhD", 
            "phone": "2163615410"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Motor function (movement speed and magnitude measured with a motion sensor) will be collected for a period of 2 hours after taking normally prescribed dose of levodopa.", 
            "measure": "Correlation between motion sensor features and clinician-rated dyskinesia severity", 
            "safety_issue": "No", 
            "time_frame": "All data will be collected within a single session not to exceed 3 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02125825"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Great Lakes NeuroTechnologies Inc.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institute on Aging (NIA)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "University of Rochester", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Johns Hopkins University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Great Lakes NeuroTechnologies Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}